Skip to main content

Molluscum Contagiosum

6
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Verrica Pharmaceuticals
Verrica PharmaceuticalsPA - West Chester
3 programs
1
2
VP-102 - Cantharidin, Topical Film Forming SolutionPhase 31 trial
VP-102 - Cantharidin, Topical Film Forming SolutionPhase 31 trial
VP-102 with applicatorPhase 21 trial
Active Trials
NCT03186378Completed33Est. Jun 2018
NCT03377790Completed266Est. Nov 2018
NCT03377803Completed262Est. Sep 2018
Combined Therapeutics
2 programs
2
Group A received cryotherpayPhase 11 trial
potassium hydroxidePhase 11 trial
Active Trials
NCT05897112Completed60Est. Apr 2023
NCT05634460Completed60Est. Aug 2022
Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
PicatoPhase 11 trial
Active Trials
NCT03336372Withdrawn0Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Verrica PharmaceuticalsVP-102 - Cantharidin, Topical Film Forming Solution
Verrica PharmaceuticalsVP-102 - Cantharidin, Topical Film Forming Solution
Verrica PharmaceuticalsVP-102 with applicator
Combined TherapeuticsGroup A received cryotherpay
Combined Therapeuticspotassium hydroxide
Leo PharmaPicato

Clinical Trials (6)

Total enrollment: 681 patients across 6 trials

NCT03377790Verrica PharmaceuticalsVP-102 - Cantharidin, Topical Film Forming Solution

Cantharidin Application in Molluscum Patients-1

Start: Mar 2018Est. completion: Nov 2018266 patients
Phase 3Completed
NCT03377803Verrica PharmaceuticalsVP-102 - Cantharidin, Topical Film Forming Solution

Cantharidin Application in Molluscum Patients

Start: Feb 2018Est. completion: Sep 2018262 patients
Phase 3Completed
NCT03186378Verrica PharmaceuticalsVP-102 with applicator

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

Start: Jun 2017Est. completion: Jun 201833 patients
Phase 2Completed
NCT05897112Combined TherapeuticsGroup A received cryotherpay

Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum

Start: Nov 2022Est. completion: Apr 202360 patients
Phase 1Completed
NCT05634460Combined Therapeuticspotassium hydroxide

Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum

Start: Mar 2022Est. completion: Aug 202260 patients
Phase 1Completed
NCT03336372Leo PharmaPicato

Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients

Start: Dec 2017Est. completion: Oct 20180
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.